Evidence map›Paper›PMID 39281063›Full record

ArticleBioMed research international2022

Preoperative CD52 Level Predicts Graft Survival following Kidney Transplantation.

Ali Ramouz, Rajan Nikbakhsh, Elias Khajeh, Mahmoud Sadeghi, Volker Daniel, Paul Schmitzler, Christian Morath, Martin Zeier, Arianeb Mehrabi, Hani Oweira

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BioMed research international, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Ali RamouzDepartment of General Visceral, and Transplantation Surgery, University of Heidelberg, 69120 Heidelberg, Germany.
Rajan NikbakhshDepartment of General Visceral, and Transplantation Surgery, University of Heidelberg, 69120 Heidelberg, Germany.ORCID https://orcid.org/0000-0002-3185-0871
Elias KhajehDepartment of General Visceral, and Transplantation Surgery, University of Heidelberg, 69120 Heidelberg, Germany.
Mahmoud SadeghiTransplantation Immunology, University of Heidelberg, 69120 Heidelberg, Germany.
Volker DanielTransplantation Immunology, University of Heidelberg, 69120 Heidelberg, Germany.
Paul SchmitzlerCenter for Infectious Disease Virology, University of Heidelberg, 69120 Heidelberg, Germany.
Christian MorathDivision of Nephrology, University of Heidelberg, 69120 Heidelberg, Germany.
Martin ZeierDivision of Nephrology, University of Heidelberg, 69120 Heidelberg, Germany.
Arianeb MehrabiDepartment of General Visceral, and Transplantation Surgery, University of Heidelberg, 69120 Heidelberg, Germany.ORCID https://orcid.org/0000-0003-2843-1390
Hani OweiraDepartment of Surgery Medical Faculty Mannheim, University of Heidelberg, 68167 Mannheim, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Several factors have been reported to affect graft survival following kidney transplantation. CD52 molecules may increase T cell proliferation and activation, which may contribute to acute graft rejection and graft survival. In the current study, we studied the possible value of preoperative CD52 levels in predicting graft survival following renal transplantation. Ninety-six patients with end-stage renal disease who had kidney transplantation were included in the study from our prospective cohort. Blood samples were taken one day before surgery, and plasma CD52 levels were measured using ELISA (Cloud-Clone Corp., Houston, TX, USA). Acute rejection, acute tubular necrosis, delayed graft function, graft loss, BK infection, cytomegalovirus infection, and graft survival were evaluated. The mean age of recipients was 50.08 ± 12.82 years, and 64.6% were male. The incidence of delayed graft function, acute rejection, graft loss (

Identifiers

PMID39281063
PMCPMC11401654

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.